There are currently 3 drugs being studied that target CGRP. One drug showed a reduction of 66% compared to a 52% placebo group reduction in migraine days. Sixteen percent were headache-free while none of the placebo patients were. The second drug had a 63% reduction compared to 42% in placebo group. No safety issues were noted.
Our center is a site in a research study with a third drug, which is a monoclonal antibody directed against CGRP, a pain transmitter critical in the migraine process.